8-K current report · filed Aug 6, 2026

10x Genomics, Inc. (TXG) 8-K Current Report: August 6, 2026

Item EX-99.1Item 2.02TXG overview

Short answer

10x Genomics, Inc. (TXG) filed an 8-K current report with the SEC on August 6, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Q2 2026 financial results announced for the quarter ended June 30, 2026.

10x Genomics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 2026 financial results announced for the quarter ended June 30, 2026
  • Full revenue, earnings, guidance and operating details in Exhibit 99.1, the accompanying earnings release

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue $151.0M, down from $172.9M, but underlying revenue excluding settlements grew 3% year over year
  • Consumables revenue $130.8M, up from $122.2M, offset by instrument revenue falling to $7.7M from $14.5M
  • Gross margin 74%, up from 72%, helped by lower manufacturing costs and $2.6M in tariff refunds
  • Net loss $17.9M, or $0.14 per share, versus net income $34.5M, or $0.28, due largely to smaller settlement gains
  • Full-year revenue guidance raised to $610M-$630M, signaling improved confidence despite continued operating losses and $552.0M liquidity

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other 10x Genomics, Inc. 8-K filings

Get the next TXG 8-K as it lands

Follow TXG for push alerts, or ask the research agent what this filing means.